Apogee Therapeutics trims board as two directors resign

Apogee Therapeutics, Inc. reported that two directors, Andrew Gottesdiener, M.D. and Peter Harwin, have notified the Board of their intention to resign effective May 11, 2026.

Rhea-AI Filing Summary

Apogee Therapeutics, Inc. reported that two directors, Andrew Gottesdiener, M.D. and Peter Harwin, have notified the Board of their intention to resign effective May 11, 2026. The company states these resignations are not due to any disagreement regarding its operations, policies or practices.

Following their departure, the size of the Board will be reduced from nine directors to seven directors, consolidating governance among a smaller group of board members.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Effective resignation date: May 11, 2026 Board size before resignations: nine directors Board size after resignations: seven directors +1 more

4 metrics

Effective resignation date May 11, 2026 Directors’ Board resignations become effective

Board size before resignations nine directors Board composition prior to May 11, 2026

Board size after resignations seven directors Board composition effective May 11, 2026

Notice date April 21, 2026 Date both directors notified the Board

Key Terms

Board of Directors, Emerging growth company, Item 5.02, Securities Exchange Act of 1934

4 terms

Board of Directors financial

"each notified the Board of Directors (the “Board”) of Apogee Therapeutics, Inc."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

Emerging growth company regulatory

"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Item 5.02 regulatory

"Item 5.02 Departure of Directors or Certain Officers; Election of Directors"

Securities Exchange Act of 1934 regulatory

"Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Apogee Therapeutics (APGE) disclose in this 8-K filing?

Apogee Therapeutics disclosed that directors Andrew Gottesdiener, M.D. and Peter Harwin plan to resign from the Board effective May 11, 2026. The company also stated that the resignations are not due to any disagreement regarding its operations, policies, or practices.

When will the Apogee Therapeutics (APGE) director resignations become effective?

The resignations of Andrew Gottesdiener, M.D. and Peter Harwin from Apogee Therapeutics’ Board will become effective on May 11, 2026. Both directors notified the Board of their intentions on April 21, 2026, providing several weeks of transition time before their departures.

Why are the Apogee Therapeutics (APGE) directors resigning from the Board?

Apogee Therapeutics stated that the resignations of Andrew Gottesdiener, M.D. and Peter Harwin are not the result of any disagreement with the company. This includes no disagreement on operations, policies, or practices, suggesting routine or personal reasons rather than governance conflicts.

How will Apogee Therapeutics’ (APGE) Board size change after the resignations?

After the resignations of Andrew Gottesdiener, M.D. and Peter Harwin become effective on May 11, 2026, Apogee Therapeutics’ Board will shrink from nine directors to seven. The filing specifies this reduction in Board size as part of the post-resignation governance structure.

Who signed the Apogee Therapeutics (APGE) 8-K reporting these Board changes?

The 8-K reporting the director resignations at Apogee Therapeutics was signed by Michael Henderson, M.D., the company’s Chief Executive Officer. His signature indicates the company’s formal authorization and confirmation of the disclosed Board changes and related details.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 04:15 PM EDT Learn about SEC filing dates

false000197464000019746402026-04-212026-04-21

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 21, 2026

Apogee Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41740	93-4958665
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
221 Crescent St., Bldg 17, Suite 102b
Waltham, Massachusetts				02453
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 394-5230

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		APGE		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 21, 2026, Andrew Gottesdiener, M.D. and Peter Harwin each notified the Board of Directors (the “Board”) of Apogee Therapeutics, Inc. (the “Company”) of his intention to resign from the Board effective May 11, 2026. The resignations of Dr. Gottesdiener and Mr. Harwin are not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The size of the Board will be reduced from nine directors to seven directors effective May 11, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Apogee Therapeutics, Inc.
Date:	April 24, 2026	By:	/s/ Michael Henderson, M.D.
			Michael Henderson, M.D. Chief Executive Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 23.4 KB